Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AB Science

< Previous 1 2 Next >
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
From AB Science
Via GlobeNewswire
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
From AB Science
Via GlobeNewswire
AB Science announces a slight delay in the publication of its 2023 annual financial report
From AB Science
Via GlobeNewswire
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
From AB Science
Via GlobeNewswire
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
From AB Science
Via GlobeNewswire
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
From AB Science
Via GlobeNewswire
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
From AB Science
Via GlobeNewswire
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
From AB Science
Via GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
From AB Science
Via GlobeNewswire
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
From AB Science
Via GlobeNewswire
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
From AB Science
Via GlobeNewswire
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
From AB Science
Via GlobeNewswire
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
From AB Science
Via GlobeNewswire
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
From AB Science
Via GlobeNewswire
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
From AB Science
Via GlobeNewswire
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
From AB Science
Via GlobeNewswire
AB Science reports its revenues for the year 2022 and provides an update on its activities
From AB Science
Via GlobeNewswire
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
From AB Science
Via GlobeNewswire
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
From AB Science
Via GlobeNewswire
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
From AB Science
Via GlobeNewswire
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
From AB Science
Via GlobeNewswire
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
From AB Science
Via GlobeNewswire
AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
From AB Science
Via GlobeNewswire
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
From AB Science
Via GlobeNewswire
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
From AB Science
Via GlobeNewswire
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
From AB Science
Via GlobeNewswire
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
From AB Science
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.